Search results
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development...
Morningstar· 7 days agoTÜBINGEN, GERMANY AND BOSTON, MA / ACCESSWIRE / May 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based ...